Investigating Dato-DXd with or without Osimertinib for advanced lung cancer
Official title: A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)
Run by AstraZeneca · NCT06417814 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing a new treatment called Dato-DXd, with and without another drug called osimertinib, to see if it helps people with advanced lung cancer who have already tried other therapies.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 130 Years |
| Sex | All |
| Enrollment | 744 (estimated) |
| Sponsor | AstraZeneca Industry-sponsored |
| Drugs / interventions | osimertinib, chemotherapy, immunotherapy, radiation |
| Locations | 302 sites (Fayetteville, Arkansas and 301 other locations) |
| Trial ID | NCT06417814 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with histologically confirmed non-squamous NSCLC who have documented EGFR mutations and have experienced disease progression on prior osimertinib treatment.
✕Probably not a fit
Patients with squamous cell carcinoma or those who have not received prior osimertinib may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase III, open-label, multicenter study evaluates the efficacy and safety of Dato-DXd, both in combination with osimertinib and as a monotherapy, compared to standard platinum-based doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Participants will be randomized into three groups to assess progression-free survival (PFS) and safety outcomes. The study aims to provide insights into treatment options for patients whose disease has progressed after prior osimertinib therapy.
Why it matters
Potential benefit: If successful, this study could offer a new effective treatment option for patients with advanced EGFR-mutated NSCLC.
How similar studies have gone: Other studies have shown promising results with similar targeted therapies in EGFR-mutated lung cancer, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically or cytologically confirmed non-squamous NSCLC. * Must have evidence of documented pre-existing EGFRm information (EGFRm known to be associated with (epidermal growth factor receptor \[EGFR\] tyrosine kinase inhibitor \[TKis\] sensitivity \[Ex19del, L858R, G719X, S768I, or L861Q\], either alone or in combination with other EGFR mutations, which may include T790M). * Documented extra-cranial radiologic progression on prior osimertinib monotherapy (as most recent line of treatment) in the adjuvant, locally advanced, or metastatic setting. * Less than or equal to (\<=2) prior lines of EGFR TKIs (osimertinib is the only permitted prior third generation EGFR TKI). * At least one lesion, not previously irradiated, that qualifies as a RECIST v1.1 TL at baseline and can be accurately measured at baseline. * World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate bone marrow reserve and organ function within 7 days before randomization. Exclusion Criteria: * Use of chemotherapy, vascular endothelial growth factor inhibitor, immunotherapy or any anti-cancer therapy in the metastatic setting. Platinum-based chemotherapy in non-metastatic setting within 12 months prior to randomization. * History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 2 years before the first dose of study intervention. * Any evidence of severe or uncontrolled systemic diseases, including, but not limited to active bleeding diseases, active infection, active ILD/pneumonitis, cardiac disease. * Has significant third-space fluid retention (example \[eg.\], ascites or pleural effusion) as judged by the investigator and is not amenable for required repeated drainage. * History of non-infectious ILD/pneumonitis including radiation pneumonitis that required steroids or drug-induced ILD, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening. * Has severe pulmonary function compromise resulting from intercurrent pulmonary illnesses. * Unstable spinal cord compression and/or unstable brain metastases. * Participants with symptomatic brain metastases (including leptomeningeal involvement). * Clinically significant corneal disease. * Uncontrolled infection requiring systemic antibiotics, antivirals, or antifungals, suspected infections or inability to rule out infections. Use of systemic antibiotics within 14 days of randomization. * Has known human immunodeficiency virus (HIV) infection that is not well controlled.
Where it's running
-
Research Site
Fayetteville, Arkansas, United States Recruiting -
Research Site
Fountain Valley, California, United States Recruiting -
Research Site
La Jolla, California, United States Recruiting -
Research Site
Colorado Springs, Colorado, United States Recruiting -
Research Site
Fort Collins, Colorado, United States Recruiting -
Research Site
Jacksonville, Florida, United States Recruiting
Show 44 more locations
-
Research Site
Athens, Georgia, United States Recruiting -
Research Site
Evanston, Illinois, United States Recruiting -
Research Site
Louisville, Kentucky, United States Recruiting -
Research Site
Baltimore, Maryland, United States Recruiting -
Research Site
Bethesda, Maryland, United States Recruiting -
Research Site
Boston, Massachusetts, United States Recruiting -
Research Site
Detroit, Michigan, United States Recruiting -
Research Site
Kansas City, Missouri, United States Recruiting -
Research Site
Omaha, Nebraska, United States Recruiting -
Research Site
Morristown, New Jersey, United States Recruiting -
Research Site
Northfield, New Jersey, United States Recruiting -
Research Site
New York, New York, United States Recruiting -
Research Site
The Bronx, New York, United States Recruiting -
Research Site
Maumee, Ohio, United States Recruiting -
Research Site
Pittsburgh, Pennsylvania, United States Recruiting -
Research Site
Chattanooga, Tennessee, United States Recruiting -
Research Site
Nashville, Tennessee, United States Recruiting -
Research Site
Fairfax, Virginia, United States Recruiting -
Research Site
Fitzroy, Australia Recruiting -
Research Site
Heidelberg, Australia Recruiting -
Research Site
Kogarah, Australia Recruiting -
Research Site
Liverpool, Australia Recruiting -
Research Site
Nedlands, Australia Recruiting -
Research Site
Port Macquarie, Australia Recruiting -
Research Site
St Leonards, Australia Recruiting -
Research Site
Westmead, Australia Recruiting -
Research Site
Woolloongabba, Australia Recruiting -
Research Site
Charleroi, Belgium Recruiting -
Research Site
Edegem, Belgium Recruiting -
Research Site
Ghent, Belgium Recruiting -
Research Site
Hasselt, Belgium Recruiting -
Research Site
Jette, Belgium Recruiting -
Research Site
La Louvière, Belgium Recruiting -
Research Site
Leuven, Belgium Recruiting -
Research Site
Namur, Belgium Recruiting -
Research Site
Roeselare, Belgium Recruiting -
Research Site
Itajaí, Brazil Recruiting -
Research Site
Brampton, Ontario, Canada Recruiting -
Research Site
Toronto, Ontario, Canada Recruiting -
Research Site
Toronto, Ontario, Canada Recruiting -
Research Site
Montreal, Quebec, Canada Recruiting -
Research Site
Baoding, China Recruiting -
Research Site
Beijing, China Recruiting -
Research Site
Beijing, China Recruiting
+252 more sites. See ClinicalTrials.gov for the full list.
Study contacts
- Study coordinator: AstraZeneca Clinical Study Information Center
- Email: information.center@astrazeneca.com
- Phone: 1-877-240-9479
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Firmonertinib versus standard EGFR drugs as first treatment for advanced NSCLC with EGFR PACC mutations
This trial tests whether daily firmonertinib works better than standard EGFR drugs (osimertinib or afatinib) as the first treatment for people with advanced NSCLC that has EGFR PACC mutations.
-
Comparing osimertinib alone versus with chemotherapy for lung cancer
This study is testing whether adding chemotherapy to osimertinib can help people with advanced lung cancer and an EGFR mutation feel better and live longer.
-
Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases
This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.
-
Osimertinib with Cyclosporine A for EGFR-mutant NSCLC
This phase II study tests whether adding cyclosporine A to osimertinib helps people with EGFR-mutant metastatic NSCLC who still have detectable tumor DNA in blood.
-
DS-3939a in solid tumors and non-small cell lung cancer
This study tests DS-3939a, alone or with other anticancer drugs, in adults with solid tumors including locally advanced or metastatic NSCLC to see if it is safe and helps control the disease.
-
Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic NSCLC
This trial tests whether surgically removing the main lung tumor, after initial osimertinib therapy, helps people with EGFR-mutant oligometastatic non-small cell lung cancer live longer without disease progression.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.